Bronchiectasis

59

Pipeline Programs↗

22

Active Trials↗

26

Companies Involved↗

Bronchiectasis is a moderately active landscape with 59 programs across 26 companies. The most active players are Ansun Biopharma, Inc., Shanghai Huilun Pharmaceutical Co., Ltd., Novartis. 21 therapies are approved with 12 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

64/100

Pipeline Velocity

19/100

Mech. Concentration

27/100

Completion Rate

88/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Ansun Biopharma, Inc.

2 programs

Shanghai Huilun Pharmaceutical Co., Ltd.

2 programs

Novartis

1 program

Regend Therapeutics

1 program

GSK

4 programs

Hyundai Pharmaceutical Co., LTD.

1 program

Pipeline

Programs by Phase

Analysis

Modality Breakdown

97%

Small molecule

69 of 71 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 71 classified programs, each share of the total. Modality classified for 96% of 77 pipeline programs.

Analysis

Trial Status

75

clinical trials

Completed30 · 40%

Unknown status19 · 25%

Recruiting17 · 23%

Not yet recruiting4 · 5%

Terminated3 · 4%

Withdrawn1 · 1%

Other1 · 1%

Clinical Trials

Trial Activity

75 trials

Benefits of Inhalation of Hypertonic Saline Solution Prior to Physiotherapy ELTGOL Technique in Bronchiectasis

Recruiting·IInstitut d'Investigació Biomèdica de Girona Dr. Josep Trueta·Phase 3·NCT06443658·57 enrolled

Bronchoscopic Levofloxacin, Gentamicin, or Sham for Acute Exacerbation of Bronchiectasis

Recruiting·—·Phase 4·NCT06209047·315 enrolled

Efficacy and Safety of Long-term Oral Staphylococcus Albicans Tablets in Patients With Bronchiectasis

Recruiting·QQianfoshan Hospital·N/A·NCT05407792·134 enrolled

A Rhinovirus Challenge Study to Investigate Exacerbations and Immune Responses in Bronchiectasis

Recruiting·IImperial College London·N/A·NCT06931002·54 enrolled

Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis

Recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 4·NCT06093191·364 enrolled

Vitamin D Replacement in Bronchiectasis

Recruiting·QQueen Mary Hospital, Hong Kong·Phase 4·NCT06551337·104 enrolled

HFNC in Management of Bronchiectasis Exacerbation

Recruiting·—·N/A·NCT05741697·20 enrolled

Research on the Mechanism Affecting Progression of Bronchiectasis

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·N/A·NCT05731427·150 enrolled

Airway Clearance Technique of Oscillation and Lung Expansion in Bronchiectasis

Recruiting·SShanghai Pulmonary Hospital, Shanghai, China·N/A·NCT06393257·96 enrolled

Itraconazole Therapy In Bronchiectasis With Airway Mold

Recruiting·MMayo Clinic·Phase 4·NCT07283497·30 enrolled

Clinical Study on the Treatment of Stable Bronchiectasis With Bailing Capsules Combined With Guben Kechuan Granules

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT07114120·214 enrolled

Comparison of Two Antibiotic Regimens for the Treatment of Early Airways Infection With PA in Adults With Bronchiectasis

Recruiting·—·Phase 2·NCT06368804·196 enrolled

Regional Phenotyping of CF and Non-CF Bronchiectasis

Recruiting·—·N/A·NCT04793867·100 enrolled

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis

Recruiting· Chiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.·Phase 1/2·NCT06166056·45 enrolled

Natural History of Bronchiectasis

Recruiting·National Heart, Lung, and Blood Institute (NHLBI)·N/A·NCT00943514·900 enrolled

Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)